All News

2021

March

Illustration of planet earth
Featured News / Mar 01, 2021

On a mission to transform planetary health

The first One Young World – Novartis Caucus took place virtually on February 11, 2021.

Read More

February

Media Release / Feb 08, 2021

Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia

Read More

January

Media Release / Jan 29, 2021

Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

Read More
Media Release / Jan 29, 2021

Novartis renews WHO medicine donation pledge with aim of ending leprosy

Read More
Three engineers walking in the modern and bright lab
Featured News / Jan 26, 2021

Novartis 2020 Financial Results

Novartis announces the company’s fourth quarter and 2020 full year financial results.

Read More
Media Release / Jan 26, 2021

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

Read More
Media Release / Jan 19, 2021

Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa

Read More
2020

December

Media Release / Dec 14, 2020

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Read More
Media Release / Dec 08, 2020

Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial

Read More
Media Release / Dec 04, 2020

Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More